Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myeloma-Reference-Cited by-同舟云学术

Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myeloma

Published:2022-05-03 Issue:3 Volume:198 Page:503-514
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Cho Hyunsoo¹^ORCID,Shin Saeam²^ORCID,Chung Haerim¹,Jang Ji Eun¹,Kim Yu Ri¹,Cheong June‐Won¹,Min Yoo Hong¹,Lee Seung‐Tae²,Choi Jong Rak²,Kim Jin Seok¹^ORCID

Affiliation:

1. Division of Hematology, Department of Internal Medicine Yonsei University College of Medicine Seoul Republic of Korea

2. Department of Laboratory Medicine Yonsei University College of Medicine Seoul Republic of Korea

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18211

Reference43 articles.

1. Multiple myeloma

2. Roadmap to cure multiple myeloma

3. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

4. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

5. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable Residual Disease of Multiple Myeloma: Current Methods and Future Directions;Laboratory Medicine Online;2024-07-01

2. Advances in minimal residual disease monitoring in multiple myeloma;Critical Reviews in Clinical Laboratory Sciences;2023-05-26

3. Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside;Experimental Hematology & Oncology;2022-09-03